Hyundai Bioscience Co. Ltd Asset Resilience Ratio
Hyundai Bioscience Co. Ltd asset resilience ratio. Hyundai Bioscience Co. Ltd (048410) has an Asset Resilience Ratio of 18.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hyundai Bioscience Co. Ltd (048410) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hyundai Bioscience Co. Ltd (2002–2025)
Asset resilience ratio of Hyundai Bioscience Co. Ltd from 2002 to 2025. This chart shows how Hyundai Bioscience Co. Ltd's Asset Resilience Ratio has changed over time. Read Hyundai Bioscience Co. Ltd (048410) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hyundai Bioscience Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 048410 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩24.75 Billion | 18.85% |
| Total Liquid Assets | ₩24.75 Billion | 18.85% |
Asset Resilience Insights
- Good Liquidity Position: Hyundai Bioscience Co. Ltd maintains a healthy 18.85% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Hyundai Bioscience Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Hyundai Bioscience Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Hyundai Bioscience Co. Ltd Asset Resilience Ratio by Year (2002–2025)
Hyundai Bioscience Co. Ltd asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Hyundai Bioscience Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.57% | ₩17.74 Billion ≈ $12.02 Million |
₩130.74 Billion ≈ $88.60 Million |
-5.37pp |
| 2023-12-31 | 18.94% | ₩10.00 Billion ≈ $6.78 Million |
₩52.79 Billion ≈ $35.78 Million |
-8.88pp |
| 2022-12-31 | 27.82% | ₩18.73 Billion ≈ $12.69 Million |
₩67.33 Billion ≈ $45.63 Million |
+0.26pp |
| 2021-12-31 | 27.57% | ₩22.20 Billion ≈ $15.04 Million |
₩80.53 Billion ≈ $54.57 Million |
+6.76pp |
| 2020-12-31 | 20.81% | ₩19.21 Billion ≈ $13.02 Million |
₩92.31 Billion ≈ $62.56 Million |
+9.65pp |
| 2019-12-31 | 11.16% | ₩7.06 Billion ≈ $4.78 Million |
₩63.24 Billion ≈ $42.85 Million |
+5.30pp |
| 2018-12-31 | 5.85% | ₩3.16 Billion ≈ $2.14 Million |
₩54.01 Billion ≈ $36.60 Million |
-9.32pp |
| 2017-12-31 | 15.17% | ₩7.51 Billion ≈ $5.09 Million |
₩49.50 Billion ≈ $33.54 Million |
-8.69pp |
| 2016-12-31 | 23.86% | ₩12.74 Billion ≈ $8.63 Million |
₩53.38 Billion ≈ $36.18 Million |
+21.76pp |
| 2015-12-31 | 2.10% | ₩910.00 Million ≈ $616.69K |
₩43.41 Billion ≈ $29.42 Million |
-0.68pp |
| 2014-12-31 | 2.77% | ₩910.00 Million ≈ $616.69K |
₩32.81 Billion ≈ $22.23 Million |
+2.32pp |
| 2013-12-31 | 0.45% | ₩140.09 Million ≈ $94.94K |
₩30.84 Billion ≈ $20.90 Million |
+0.45pp |
| 2012-12-31 | 0.00% | ₩66.00K ≈ $44.73 |
₩32.06 Billion ≈ $21.73 Million |
-5.43pp |
| 2011-12-31 | 5.43% | ₩1.65 Billion ≈ $1.12 Million |
₩30.47 Billion ≈ $20.65 Million |
+5.11pp |
| 2010-12-31 | 0.32% | ₩154.50 Million ≈ $104.71K |
₩48.45 Billion ≈ $32.83 Million |
-4.12pp |
| 2009-12-31 | 4.43% | ₩2.71 Billion ≈ $1.84 Million |
₩61.19 Billion ≈ $41.46 Million |
+0.43pp |
| 2008-12-31 | 4.01% | ₩3.51 Billion ≈ $2.38 Million |
₩87.53 Billion ≈ $59.31 Million |
-13.64pp |
| 2007-12-31 | 17.65% | ₩18.21 Billion ≈ $12.34 Million |
₩103.16 Billion ≈ $69.91 Million |
+15.06pp |
| 2006-12-31 | 2.58% | ₩2.73 Billion ≈ $1.85 Million |
₩105.52 Billion ≈ $71.51 Million |
-15.58pp |
| 2005-12-31 | 18.16% | ₩41.93 Billion ≈ $28.41 Million |
₩230.83 Billion ≈ $156.43 Million |
+3.53pp |
| 2004-12-31 | 14.64% | ₩32.91 Billion ≈ $22.30 Million |
₩224.80 Billion ≈ $152.34 Million |
+1.80pp |
| 2003-12-31 | 12.84% | ₩31.14 Billion ≈ $21.10 Million |
₩242.55 Billion ≈ $164.37 Million |
-4.91pp |
| 2002-12-31 | 17.74% | ₩35.59 Billion ≈ $24.12 Million |
₩200.60 Billion ≈ $135.94 Million |
-- |
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.